Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Decreases By 55.3%

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 68,300 shares, a drop of 55.3% from the November 15th total of 152,900 shares. Based on an average daily volume of 471,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.5% of the company’s shares are short sold.

Entero Therapeutics Stock Performance

Shares of Entero Therapeutics stock traded down $0.04 on Friday, hitting $0.58. 72,549 shares of the company’s stock traded hands, compared to its average volume of 364,733. Entero Therapeutics has a one year low of $0.19 and a one year high of $14.51. The firm’s 50-day moving average price is $0.57 and its two-hundred day moving average price is $0.86.

Entero Therapeutics (NASDAQ:ENTO) last announced its quarterly earnings results on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. As a group, equities research analysts predict that Entero Therapeutics will post -1.13 EPS for the current year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.